Sugi Predict

Sugi Predict / Compounds / SCHEMBL14949321

SCHEMBL14949321

SCHEMBL14949321

Cc1cccc(Nc2nnc(-c3cccc(Oc4ccnc5ccccc45)c3)[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.46
▸ EGFR P00533 1/20 0.41
▸ MET P08581 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.39
▸ BRAF P15056 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ TNNI3K Q59H18 1/20 0.38
▸ FGFR2 P21802 2/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ LCK P06239 1/20 0.36
▸ TEK Q02763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949367 0.93 KDR (0.42) KDREGFRMETPDGFRAFGFR2
SCHEMBL14949372 0.93 KDR (0.42) KDREGFRMETPDGFRAMAPT
SCHEMBL14949644 0.91 KDR (0.44) KDREGFRMETHTTHIF1A
SCHEMBL14949353 0.89 KDR (0.45) KDREGFRMETPDGFRAMAPT
SCHEMBL14949343 0.89 KDR (0.40) KDREGFRMETPDGFRASMN1; SMN2
SCHEMBL14949313 0.89 KDR (0.46) KDRMETPDGFRAFGFR2LCK
SCHEMBL14949351 0.89 KDR (0.41) KDRMETPDGFRALCKTEK
SCHEMBL14949350 0.87 MAPT (0.43) KDRMETHTTMAPTABCB1
SCHEMBL14949385 0.86 SYK (0.41) KDRMETPDGFRAFGFR2TEK
SCHEMBL12336272 0.86 BRAF (0.54) KDREGFRHTTABCG2BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 KDR 533/4885EGFR 499/4885MET 770/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDR 533/4885EGFR 499/4885MET 770/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDR 533/4885EGFR 499/4885MET 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.